Welcome to our dedicated page for Orasure Tech news (Ticker: OSUR), a resource for investors and traders seeking the latest updates and insights on Orasure Tech stock.
OraSure Technologies, Inc. (NASDAQ: OSUR) is a medical devices company focused on point-of-need and home diagnostic tests and sample management solutions. The OraSure news stream on this page highlights company announcements, financial updates, product milestones, governance changes, and shareholder developments that shape the OSUR investment story.
News coverage commonly includes quarterly and year-to-date financial results, where OraSure reports net revenues, gross margins, operating performance, and the mix of diagnostics, sample management solutions, COVID-19 diagnostics, risk assessment testing, molecular services, and non-product revenues. Earnings releases also discuss core business trends, cash and cash equivalents, and share repurchase activity, providing context on the company’s financial condition and capital allocation.
Investors and industry followers can also track product and innovation milestones, such as FDA submissions for the Sherlock rapid molecular self-test for Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG) and the Colli-Pee at-home urine collection device for sexually transmitted infections. Additional updates may cover launches of research-use products like HEMAcollect PROTEIN, agreements with partners such as GeneDx, and participation in initiatives like the ENDO1000 project.
Governance and corporate developments feature prominently in OraSure news. Recent items include board refreshment, the appointment of new independent directors, changes in board leadership, and the hiring of senior executives such as the Chief Commercial Officer. News also documents shareholder engagement, including communications from Altai Capital Management regarding board nominations and perspectives on company performance and strategy.
By following this OSUR news page, readers can review a chronological record of OraSure’s press releases and related items, covering earnings, product pipeline progress, strategic initiatives, board composition, and shareholder actions, all drawn from official company and partner announcements.
OraSure Technologies, a leader in point of care diagnostics, announced that Dr. Stephen S. Tang, Ph.D., President and CEO, will present at the Jefferies 2020 Healthcare Conference on June 2, 2020, at 3:00 PM EST. The event will be available for live streaming on OraSure's website, and a replay will be accessible for seven days post-event. OraSure Technologies focuses on providing accurate health information and offers a range of diagnostic products and services globally, aimed at improving health and wellness.
OraSure Technologies (NASDAQ: OSUR) announced that its OMNIgene®·ORAL saliva collection device (OM-505) received FDA Emergency Use Authorization (EUA) for at-home SARS-CoV-2 testing by P23 Labs. This device allows self-collection of saliva samples, enhancing testing accessibility for individuals unable to visit collection centers. This marks the second EUA for a DNA Genotek collection device, following the ORAcollect®·RNA kit’s EUA earlier in May. OraSure aims to boost COVID-19 testing while reducing infection risks and PPE demands.
Diversigen, a subsidiary of OraSure Technologies (NASDAQ: OSUR), has been selected by Nom Nom™, a pet health brand, as their preferred provider for microbiome sequencing and analysis services. This partnership aims to enhance pet health through personalized nutrition informed by microbiome data. Nom Nom has conducted significant research on pet gut health, including a major study analyzing 238 pets. Diversigen's expertise in metagenomics and bioinformatics will support this initiative, utilizing advanced sequencing solutions to deepen the understanding of pet health issues linked to the microbiome.
BETHLEHEM, Pa., May 15, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies (NASDAQ: OSUR) announces that Dr. Stephen S. Tang, President and CEO, will present at the UBS Virtual Global Healthcare Conference on May 20, 2020, at 10:50 AM EST. The conference will be webcast live, and interested investors can access it via the company's website. A replay will be available for seven days post-event. OraSure provides crucial diagnostic tools and services globally, aiding in the detection of medical conditions. For more details, visit www.orasure.com.
OraSure Technologies, Inc. (NASDAQ: OSUR) announced its 2020 Annual Meeting of Stockholders will be held virtually on May 19, 2020, at 10:00 a.m. EDT. Stockholders can access the live webcast via here. Participants need their control number to vote or ask questions. A replay of the meeting will be accessible within 24 hours and archived for seven days.
OraSure Technologies (NASDAQ: OSUR) has announced the unification of its microbiome service offerings under the Diversigen brand, combining its CoreBiome and Diversigen subsidiaries. This strategic rebranding aims to enhance service quality and innovation in the fast-growing microbiome industry, backed by over a century of combined scientific experience and extensive publication credentials. The move is expected to streamline service delivery and provide clients with advanced solutions for metagenomics, bioinformatics, and statistical analysis.
OraSure Technologies, Inc. (NASDAQ: OSUR) reported a net revenue increase of 5% to $31.6 million for Q1 2020, driven by a 9% growth in product and service revenues. International sales of OraQuick® HIV products surged 74%.
However, the company experienced a net loss of $7.3 million, compared to a loss of $3.3 million in Q1 2019. Cash and investments totaled $176.2 million as of March 31, 2020. Additionally, the pandemic prompted the withdrawal of full-year 2020 financial guidance due to uncertainty, despite potential opportunities in COVID-19 testing solutions.
OraSure Technologies (NASDAQ: OSUR) has announced the appointment of Lisa Nibauer as Executive Vice President, Business Unit Leader for Infectious Disease, succeeding Tony Zezzo, who will retire. Ms. Nibauer, effective May 11, 2020, brings extensive experience from BD Becton Dickinson, overseeing $1.6 billion in revenue. Zezzo, instrumental in commercializing key products like the OraQuick® HCV Rapid Antibody test, will assist in the transition. Additionally, Charles W. Patrick will retire from the Board of Directors on May 16, 2020, after a significant tenure since 2006.